Security
TScan Therapeutics, Inc. Common Stock · TCRX
TCRXNASDAQCommon stockCurrentCIK 1783328Updated Oct 4, 2026
TCRX price & chart
Loading TradingView…
NASDAQ:TCRX on TradingView ↗About the company
TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company is advancing two therapeutics candidates through IND-enabling studies to treat solid tumors using in vivo-engineered TCR-T cells. In addition, the Company is seeking partnerships for its heme and autoimmune programs. To learn more, visit www.tscan.com and connect with us on LinkedIn and X.
In the news
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting ↗
Seeking Alpha
TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study - Slideshow ↗
TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study Transcript ↗
TScan Therapeutics GAAP EPS of -$0.22 misses by $0.01, revenue of $1M misses by $1.5M ↗
Recent filings
4 filing
4 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Costs Associated with Exit or Disposal Activities · Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure · Other Events
Items 2.05, 3.01, 5.02, 7.01, 8.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 228,789,000Source | 371,118,000Source | 272,149,000Source | 199,091,000Source |
| Property, Plant and Equipment, NetUSD | 8,706,000Source | 7,242,000Source | 7,742,000Source | 10,100,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 152,406,000Source | 178,689,000Source | 133,359,000Source | 120,027,000Source |
| Assets, CurrentUSD | 157,208,000Source | 292,722,000Source | 194,237,000Source | 124,127,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,802,000Source | 2,612,000Source | 2,193,000Source | 4,100,000Source |
| Operating Lease, Right-of-Use AssetUSD | 57,743,000Source | 64,357,000Source | 63,492,000Source | 59,102,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 105,666,000Source | 130,148,000Source | 121,282,000Source | 99,657,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | 0Source | — | — |
| Retained Earnings (Accumulated Deficit)USD | -504,862,000Source | -375,096,000Source | -247,597,000Source | -158,379,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | 51,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 123,123,000Source | 240,970,000Source | 150,867,000Source | 99,434,000Source |
| Additional Paid in Capital, Common StockUSD | 627,979,000Source | 616,009,000Source | 398,459,000Source | 257,810,000Source |
| Liabilities and EquityUSD | 228,789,000Source | 371,118,000Source | 272,149,000Source | 199,091,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 18,695,000Source | 35,956,000Source | 29,820,000Source | 17,305,000Source |
| Operating Lease, Liability, CurrentUSD | 7,167,000Source | 4,570,000Source | 3,246,000Source | 3,681,000Source |
| Accounts Payable, CurrentUSD | 1,241,000Source | 4,278,000Source | 2,374,000Source | 2,912,000Source |
| Operating Lease, Liability, NoncurrentUSD | 54,437,000Source | 60,739,000Source | 59,140,000Source | 53,013,000Source |
| Other Liabilities, NoncurrentUSD | — | 135,000Source | — | 49,000Source |
| Additional Financial Items | ||||
| Deferred Revenue, CurrentUSD | 2,619,000Source | 11,698,000Source | 10,137,000Source | 3,874,000Source |
| Deferred Revenue, NoncurrentUSD | — | 1,246,000Source | 5,622,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 32,534,000Source | 32,072,000Source | — | 29,290,000Source |
| Long-term Debt, Current MaturitiesUSD | — | — | 3,347,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 32,534,000Source | 32,072,000Source | 26,700,000Source | 29,290,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -129,766,000Source | -127,499,000Source | -89,218,000Source | -66,221,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 11,706,000Source | 9,549,000Source | 5,208,000Source | 4,551,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -3,011,000Source | 1,994,000Source | -52,000Source | 528,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -135,319,000Source | -110,822,000Source | -61,358,000Source | -66,503,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 109,372,000Source | -52,613,000Source | -60,759,000Source | -4,225,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 4,407,000Source | 3,825,000Source | 3,146,000Source | 4,225,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -336,000Source | 208,765,000Source | 135,443,000Source | 29,356,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -26,283,000Source | 45,330,000Source | 13,326,000Source | -41,372,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 157,437,000Source | 183,720,000Source | 138,390,000Source | 125,064,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 2,307,000Source | 2,881,000Source | 3,002,000Source | 660,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 11,706,000Source | 9,549,000Source | 5,208,000Source | 4,551,000Source |
| DepreciationUSD | 2,866,000Source | 4,108,000Source | 5,361,000Source | 5,137,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | -1,090,000Source | — | — |
| General and Administrative ExpenseUSD | 31,988,000Source | 30,287,000Source | 26,354,000Source | 20,352,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -129,766,000Source | -127,499,000Source | -89,218,000Source | -66,221,000Source |
| Operating ExpensesUSD | 146,138,000Source | 137,637,000Source | 114,507,000Source | 80,171,000Source |
| Other Nonoperating Income (Expense)USD | 6,047,000Source | 7,322,000Source | 4,240,000Source | 415,000Source |
| Payments of Financing CostsUSD | 200,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | 33,131,000Source | 42,414,000Source | 193,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | 29,354,000Source |
| Proceeds from Stock Options ExercisedUSD | — | 1,717,000Source | 711,000Source | 133,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 10,325,000Source | 2,816,000Source | 21,049,000Source | 13,535,000Source |
| Operating Income (Loss)USD | -135,813,000Source | -134,821,000Source | -93,458,000Source | -66,636,000Source |
| Other Nonoperating Income (Expense)USD | 6,047,000Source | 7,322,000Source | 4,240,000Source | 415,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -129,766,000Source | -127,499,000Source | -89,218,000Source | -66,221,000Source |
| Earnings Per Share, BasicUSD per share | -1Source | -1.14Source | -1.36Source | -2.75Source |
| Earnings Per Share, DilutedUSD per share | -1Source | -1.14Source | -1.36Source | -2.75Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 129,777,415Source | 111,990,417Source | 65,599,858Source | 24,048,267Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 129,777,415Source | 111,990,417Source | 65,599,858Source | 24,048,267Source |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | 2,900,000Source | 4,100,000Source | 5,400,000Source | 5,100,000Source |
| General and Administrative ExpenseUSD | 31,988,000Source | 30,287,000Source | 26,354,000Source | 20,352,000Source |
| Interest and Other IncomeUSD | 8,816,000Source | 12,065,000Source | 7,999,000Source | 1,591,000Source |
| Interest ExpenseUSD | 2,769,000Source | 3,653,000Source | 3,759,000Source | 1,176,000Source |
| Operating ExpensesUSD | 146,138,000Source | 137,637,000Source | 114,507,000Source | 80,171,000Source |
| Research and Development ExpenseUSD | 114,150,000Source | 107,350,000Source | 88,153,000Source | 59,819,000Source |
Filing attachments
d309786dex991.htm · 8-K · 2026-09-02
EX-99.1 2 d309786dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors Advances two in vivo-engineered TCR-T candidates for solid tumors to IND-enabling studies with plans to initiate Phase 1 development in Q4 2027 Reports updated data from Cohort C of the Phase 1 ALLOHA ™ study; 100% (13/13) patients currently being tracked show complete donor chimerism Pauses further enrollment in Phase 3 ALLOHA-…
Read attachment ↗d309786dex992.htm · 8-K · 2026-09-02
EX-99.2 3 d309786dex992.htm EX-99.2 EX-99.2 Corporate Presentation September 2026 Exhibit 99.2 Disclaimers and forward-looking statements This presentation and the accompanying discussion contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding TScan Therapeutics, Inc.'s (the "Company") plans, progress, and timing relating to the Company’s clinical programs and the p…
Read attachment ↗tcrx-ex99_1.htm · 8-K · 2026-08-12
EX-99.1 2 tcrx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal commercial-ready manufacturing process Cash and cash equivalents fund operations into the second quarter of 2027 WALTHAM, Mass., Aug 12, 2026 -- TScan Therapeutics, Inc.…
Read attachment ↗d103234dex991.htm · 8-K · 2026-06-22
EX-99.1 2 d103234dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA ™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation 11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chimerism following TSC-101 TSC-101 continues to be well-tolerated Company rema…
Read attachment ↗d103234dex992.htm · 8-K · 2026-06-22
EX-99.2 3 d103234dex992.htm EX-99.2 EX-99.2 Data from Cohort C of the Phase 1 ALLOHA™ Study June 2026 Exhibit 99.2 Disclaimers and forward-looking statements This presentation and the accompanying discussion contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding TScan Therapeutics, Inc.’s ("TScan or the "Company") plans, progress, and timing relating to the Company…
Read attachment ↗tcrx-ex99_1.htm · 8-K · 2026-05-06
EX-99.1 2 tcrx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2™) planned for the second quarter of 2026 Initiation of Phase 1 study of TSC-102-A01 and TSC-102-A03 targeting CD45 in patients with HLA types A*01:01 and A*03:01 planned for the…
Read attachment ↗